EGFR and colorectal carcinoma: Moreover, the observed trend toward BRAF mutations and mucinous histology is clinically relevant, as BRAF-mutant CRC is associated with poor prognosis and may respond to targeted regimens combining BRAF/MEK inhibitors with anti-EGFR therapy [27].